Zhou Chen

Dr. Zhou Chen

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2021 in Molecular Metabolism
Verified
Journal Article
Open access
JZJiaping Zheng
Jiaping Zheng
YXYunzhen Xie
Yunzhen Xie
LRLingjia Ren
Lingjia Ren
LQLiqin Qi
Liqin Qi
LWLi Wu
Li Wu
LLLibin Liu
Libin Liu
Astrocytes actively participate in energy metabolism in the brain, and astrocytic aerobic glycolysis disorder is associated with the pathology of Alzheimer's disease (AD). GLP-1 has been shown to improve cognition in AD; however, the mechanism remains unclear. The objectives of this study were to assess GLP-1's glycolytic regulation effects in AD and reveal its neuroprotective mechanisms. The Morris water maze test was used to evaluate the effects of liraglutide (an analog of GLP-1) on the cognition of 4-month-old 5×FAD mice, and a proteomic analysis and Western blotting were used to assess the proteomic profile changes. We constructed an astrocytic model of AD by treating primary astrocytes with Aβ1-42. The levels of NAD+ and lactate were examined, and the oxidative levels were assessed by a Seahorse examination. Astrocyte-neuron co-culture was performed to evaluate the effects of GLP-1 on astrocytes' neuronal support. GLP-1 improved cognition in 4-month-old 5×FAD mice by enhancing aerobic glycolysis and reducing oxidative phosphorylation (OXPHOS) levels and oxidative stress in the brain. GLP-1 also alleviated Aβ-induced glycolysis declines in astrocytes, which resulted in reduced OXPHOS levels and reactive oxygen species (ROS) production. The mechanism involved the activation of the PI3K/Akt pathway by GLP-1. Elevation in astrocytic glycolysis improved astrocyte cells' support of neurons and promoted neuronal survival and axon growth. Taken together, we revealed GLP-1's capacity to regulate astrocytic glycolysis, providing mechanistic insight into one of its neuroprotective roles in AD and support for the feasibility of energy regulation treatments for AD.

1 September 2019 in Behavioural Brain Research
Verified
Journal Article
Closed access
JAJingjing An
Jingjing An
YZYu Zhou
Yu Zhou
MZMengjun Zhang
Mengjun Zhang
YXYunzhen Xie
Yunzhen Xie
SKSujie Ke
Sujie Ke
ZCZhou Chen
Zhou Chen

1 June 2021 in Biochemical Pharmacology
Verified
Journal Article
Closed access
YXYunzhen Xie
Yunzhen Xie
JZJiaping Zheng
Jiaping Zheng
SLShiqi Li
Shiqi Li
HLHuiying Li
Huiying Li
YZYu Zhou
Yu Zhou
ZCZhou Chen
Zhou Chen

1 February 2022 in Molecular and Cellular Endocrinology
Verified
Journal Article
Closed access
MZMengjun Zhang
Mengjun Zhang
YWYubin Wu
Yubin Wu
GRGao Ruonan
Gao Ruonan
XCXinwei Chen
Xinwei Chen
RCRuiyu Chen
Ruiyu Chen
ZCZhou Chen
Zhou Chen

1 January 2022 in Diabetes, Metabolic Syndrome and Obesity
Verified
Journal Article
Open access
PDF file
YZYu Zhou
Yu Zhou
MCMingyu Chen
Mingyu Chen
LLLibin Liu
Libin Liu
ZCZhou Chen
Zhou Chen
Background: Glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1RAs) are promising weight-loss drugs, but real-world data concerning the liability of GLP-1RAs in gastrointestinal safety are lacking. We examined the differences in gastrointestinal safety between semaglutide and liraglutide. Materials and Methods: We used the US Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) database and retrieved data during the first three years of semaglutide and liraglutide approved by the FDA. Thirteen main gastrointestinal adverse drug reactions (GADRs) were evaluated. Patient demographics, treatment information, and outcome of events were summarized. Disproportionality analyses were conducted by estimating the reporting odds ratios (RORs) and 95% confidence intervals (CIs). Results: In the reported cases of semaglutide (n = 2047) and liraglutide (n = 4175), semaglutide had a higher pooled ROR and later pooled time-to-onset median of GADRs compared with those of liraglutide (5.53, 95% CI 5.23– 5.85 vs 3.95, 95% CI 3.81– 4.10; 7 days, Q1–Q3: 0– 48 vs 4 days, Q1–Q3: 0– 34.5). The thirteen GADRs associated with these two GLP-1RAs showed a significant difference in the profile of reporting risk and time-to-onset. Conclusion: GLP-1RAs produce a spectrum of distinct classes of GADRs. The individual properties of GADRs between semaglutide and liraglutide might enable incretin-based treatment of obesity to be “tailored” to the needs of each patient.

11 March 2024 in Journal of Cell Biology
Verified
Journal Article
Open access
PDF file
PLPeigang Liang
Peigang Liang
YWYuchen Wu
Yuchen Wu
SZShanyuan Zheng
Shanyuan Zheng
JZJiaqi Zhang
Jiaqi Zhang
SYShuo Yang
Shuo Yang
BWBo Wang
Bo Wang
Focal adhesions (FAs) are transmembrane protein assemblies mediating cell–matrix connection. Although protein liquid–liquid phase separation (LLPS) has been tied to the organization and dynamics of FAs, the underlying mechanisms remain unclear. Here, we experimentally tune the LLPS of PXN/Paxillin, an essential scaffold protein of FAs, by utilizing a light-inducible Cry2 system in different cell types. In addition to nucleating FA components, light-triggered PXN LLPS potently activates integrin signaling and subsequently accelerates cell spreading. In contrast to the homotypic interaction-driven LLPS of PXN in vitro, PXN condensates in cells are associated with the plasma membrane and modulated by actomyosin contraction and client proteins of FAs. Interestingly, non-specific weak intermolecular interactions synergize with specific molecular interactions to mediate the multicomponent condensation of PXN and are efficient in promoting FA assembly and integrin signaling. Thus, our data establish an active role of the PXN phase transition into a condensed membrane-associated compartment in promoting the assembly/maturation of FAs.